ExpansionNovo Nordisk expands footprint in USA Novo Nordisk realises a major expansion in Clayton, NC (USA). The project will enhance Novo Nordisk’s manufacturing capabilities with more than 1.4 million square feet of new space. more ➔
InvestmentForbion closes first Bioeconomy Fund with... Forbion BioEconomy represents a strategic expansion of Forbion’s investment scope in biotech and in the life sciences sector to address challenges relating to the environment, the growing need for a … more ➔
Drug deliveryNo more needles – Exvolvo arises wit... NLC Health Ventures (Amsterdam, The Netherlands), in partnership with Verily, the precision health technology daughter company of Alphabet/Google, will launch Exolvo Biosciences, a pioneering biotech … more ➔
ChikungunyaValneva gets approval for Chikungunya vacc... Valneva announces Health Canada approval of the world’s first chikungunya vaccine, IXCHIQ®. more ➔
TubulisTubulis from Munich doses first Patient wi...Tubulis doses first patient in phase 1/2a trial investigating ADC candidate TUB-040 in ovarian cancer and lung adenocarcinoma (NSCLC). TUB-040 is a NaPi2b-targeting Exatecan ADC based on Tubulis’ proprietary … more ➔
Biosecure actBIOSECURE Act could affect half of US biop...The BIOSECURE Act of the United States could affect more than 120 US biopharmaceutical drugs partnered with Chinese companies ‘of concern’, as named in the bill. Of these, approximately half are in clinical … more ➔
Precision fermentationDanone, Michelin and DMC Biotechnologies o...French dairy giant Danone, engineering materials group Michelin, US start-up DMC Biotechnologies and Crédit Agricole Centre France have joined forces to create the Biotech Open Platform as precision … more ➔
Cancer ImmunotherapiesResearchers identify blockers of CNS effec...German researchers have tracked down the causes for central nervous system side effects of cancer immunotherapies and blocked them in small animal models. more ➔
CROEvotec SE cashes in €20m milestoneEvotec SE has reached a predefined milestone worth €20m in the CRO’s partnership with Bristol Myers Squibb (BMS). more ➔
FinancingTacalyx’ extends seed capital financ...Glycan target specialist Tacalyx GmbH expands its seed financing to €14m to advance its anti-TACA cancer therapies. more ➔